Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 1, 2004, Pages 85-88

  Berg, Stacey L ^a,c   Stone, Jeffery ^a   Xiao, Jim J ^b   Chan, Kenneth K ^b   Nuchtern, Jed ^a   Dauser, Robert ^a   McGuffey, Leticia ^a   Thompson, Patrick ^a   Blaney, Susan M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

CSF penetration; Depsipeptide; FR901228; Pharmacokinetics

Indexed keywords

DEPSIPEPTIDE; FR 901228;

ANIMAL EXPERIMENT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG PENETRATION; FATIGUE; LEUKOPENIA; LIQUID CHROMATOGRAPHY; MONKEY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; CEREBROSPINAL FLUID; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; INFUSIONS, INTRAVENOUS; MACACA MULATTA; MALE; PEPTIDES, CYCLIC;

EID: 3042722188     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0766-5     Document Type: Article

References (25)

1. Lehrmann H, Pritchard LL, Harel-Bellan A (2002) Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86:41
2. Mahlknecht U, Hoelzer D (2000) Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 6:623
3. Kim DH, Kim M, Kwon HJ (2003) Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36:110
4. Marks PA, Richon VM, Breslow R, Rifkind RA (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13:477
5. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287
6. Vigushin DM, Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13:1
7. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M (1998) Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 58:1579
8. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241:126
9. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny M, Bates S (2000) P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83:817
10. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim K-W (2002) Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 97:290
11. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916
12. Murata M, Towatari M, Kosugi H, Tanimoto M, Ueda R, Saito H, Naoe T (2000) Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. Jpn J Cancer Res 91:1154
13. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Finn IW, Dawson NA, Grever MR (1999) Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94:1401
14. Rajgolikar G, Chan KK, Wang H-C (1998) Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res Treat 51:29
15. McCully C, Balis F, Bacher J, Phillips J, Poplack D (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40:522
16. National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington DC
17. Li Z, Chan KK (2000) A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its pre-clinical pharmacokinetics. J Pharmacol Biomed Anal 22:33
18. Chan KK, Bakhtiar R, Jiang C (1997) Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS. Invest New Drugs 15:195
19. D'Argenio D, Schumitzky A (1997) ADAPT II user's guide: Pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, University of Southern California, Los Angeles
20. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165
21. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York Basel
22. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718
23. Koch-Weser J, Sellars E (1976) Binding of drugs to serum albumin. New Engl J Med 294:311
24. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K (1994) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 47:315
25. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M (1994) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. I. Taxonomy, fermentation, isolation, physiochemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 47:301